MFA
GRCE

Millington Financial Advisors’s Grace Therapeutics GRCE Stock Holding History

Millington Financial Advisors’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,000
Closed -$59.7K – 129
2025
Q3 		$59.7K Hold
20,000
– – 0.03% 103
2025
Q2 		$67K Buy
+20,000
New +$53.2K 0.03% 103

Other funds holding GRCE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millington Financial Advisors's GRCE Position: Q4 2025 in Review

Millington Financial Advisors sold out of Grace Therapeutics (GRCE) in Q4 2025, closing a stake of 20,000 shares — an estimated $59.7K sold.

Millington Financial Advisors first reported a position in GRCE in Q2 2025 and held it in 2 quarters. The position peaked at $67K in Q2 2025. 23 funds tracked by Wall St. Rank hold GRCE as of Q4 2025.

  • Millington Financial Advisors reported no remaining Grace Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Millington Financial Advisors sold 20,000 Grace Therapeutics shares in Q4 2025, an estimated $59.7K.
  • Millington Financial Advisors first reported a position in Grace Therapeutics in Q2 2025 and held it in 2 quarters.
  • Millington Financial Advisors's Grace Therapeutics position peaked at $67K in Q2 2025.
  • 23 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2025.

Based on Millington Financial Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.